The results showed that there were significant differences in the gene expression profile of tumor tissue between the two groups of GBM patients with EGFRvIII (−) and (+) (p < 0.05) and no significant difference in the distribution of important molecular typing markers (including IDH1/2 status, 1p/19q codeletion status, MGMT promoter methylation state) were found between the two groups of GBM patients with EGFRvIII (−) and (+) (p > 0.05) (Figure 1A). This evidence concerns the gene IDH1 and glioblastoma.